JERSEY CITY, N.J.–(BUSINESS WIRE)–Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older …
First end-to-end European chip manufacturing flow proven for aerospace, defense, IoT, consumer electronics and critical infrastructure DRESDEN, Germany & DELFT, Netherlands–(BUSINESS WIRE)–#ASIC—GlobalFoundries (GF) and Qualinx today announced the successful completion of the first fully European-based, end-to-end semiconductor manufacturing flow at GlobalFoundries’ Dresden fab on its FDX technology. The milestone demonstrates that security-critical chips for aerospace, …
KDDI receives newly issued shares of Coincheck Group at $2.28 per share, an aggregate cash purchase price of $65 million, constituting 14.9% ownership of Coincheck Group’s outstanding ordinary shares AMSTERDAM–(BUSINESS WIRE)–Coincheck Group N.V. (NASDAQ: CNCK) (“Coincheck Group” or the “Company”), a Dutch public limited liability company that provides digital asset trade execution, custody, staking and …
Continue reading “Coincheck Group Announces Completion of KDDI Strategic Investment”
The expanded partnership adds Denmark, Finland, Norway and Sweden to GENESIS Pharma’s existing network of thirteen Southeast European markets. It grants rights for the commercialization of Alnylam’s RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases. ATHENS, Greece–(BUSINESS WIRE)–GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative medicines in Europe, …
Four million single cells from 200-plus donors capture human neuronal biology in tissue context, now accessible via the Chan Zuckerberg Initiative’s CZ CELLxGENE platform SAN FRANCISCO–(BUSINESS WIRE)–Crownlands, Inc., a company scaling the collection of living human neurons to generate molecular data for AI-driven drug discovery and clinical trial modeling, today announced the public release of …
Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 low, medium and high dosing strategy VESPER-1 achieved a non-placebo-adjusted weight loss of almost 16% with no plateau observed at 32 weeks on 2.4 mg weekly berobenatide …
TORONTO–(BUSINESS WIRE)–Kalloghlian Myers LLP is investigating a potential investor class action against TerraVest Industries Inc. (TSE: TVK). On June 5, 2026, TerraVest shares fell 31.6% following allegations that executive chairman Charles Pellerin tipped off family members and acquaintances ahead of a major acquisition announcement. The Journal de Montréal reported that Québec’s financial regulator obtained a …
PALO ALTO, Calif.–(BUSINESS WIRE)–Tidepool, the nonprofit leader advancing innovation in diabetes technology, today unveiled new clinical insights and research initiatives in conjunction with the American Diabetes Association’s (ADA) 86th Scientific Sessions. The company’s presentation slate focuses on the immediate utility of real-world data and Tidepool’s ongoing commitment to closing gaps in women’s health research. Today’s …
SAN DIEGO–(BUSINESS WIRE)–$PICS #Banking—Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired PicS N.V. (NASDAQ: PICS) securities pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s January 30, 2026 initial public offering (“IPO”). PicS operates one of the …
Continue reading “Investor Notice: Robbins LLP Informs Investors of the PicS N.V. Class Action”
STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), …